| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Matinas BioPharma Holdings, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying and advancing a range of potential therapeutic products. The company's innovative Lipid Nanocrystal (LNC) platform technology underpins its product development efforts. This sophisticated LNC delivery system leverages lipid nano-crystals to transport a diverse array of therapeutic agents, including small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its primary experimental drug, LYPDISO, is a proprietary, prescription-grade omega-3 free fatty acid compound engineered to address cardiovascular and metabolic disorders. Matinas BioPharma is also advancing MAT2203, an orally administered version of amphotericin B. This candidate is currently in Phase II clinical trials, where it is being evaluated for its ability to prevent invasive fungal infections in patients undergoing immunosuppressive treatment. Furthermore, MAT2501, an oral formulation of the broad-spectrum aminoglycoside antibiotic amikacin, has successfully completed Phase I clinical trials. Its aim is to combat a spectrum of multidrug-resistant bacterial infections, such as non-tuberculous mycobacterium, multidrug-resistant gram-negative, and intracellular bacterial pathogens. The company actively engages in collaborations, including a research partnership with the National Institute of Allergy and Infectious Diseases (NIAID) to further the development of Gilead's antiviral drug, remdesivir. Additionally, it has a feasibility collaboration with Genentech, Inc. focused on creating new oral drug formulations. Established in 2013, Matinas BioPharma maintains its corporate headquarters in Bedminster, New Jersey.
Over the last 12 months, insiders at Matinas BioPharma Holdings, Inc. have bought $0 and sold $0 worth of Matinas BioPharma Holdings, Inc. stock.
On average, over the past 5 years, insiders at Matinas BioPharma Holdings, Inc. have bought $0 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $16,600 was made by STERN ADAM K (director) on 2020‑08‑21.
| 2020-08-21 | STERN ADAM K | director | 20,000 0.01% | $0.83 | $16,600 | +3.36% | ||
| 2020-05-14 | LEPORE PATRICK G | director | 100,000 0.0504% | $0.73 | $73,050 | +20.81% | ||
| 2020-03-17 | Jabbour Jerome D | President and CEO | 10,000 0.0051% | $0.65 | $6,500 | +25.71% | ||
| 2020-03-17 | STERN ADAM K | director | 10,000 0.0051% | $0.65 | $6,500 | +25.71% | ||
| 2019-11-25 | Kucinski Keith A | Chief Financial Officer | 58,000 0.0387% | $1.23 | $71,160 | -26.55% | ||
| 2019-11-22 | Kucinski Keith A | Chief Financial Officer | 36,500 0.0234% | $1.20 | $43,807 | -27.98% | ||
| 2019-11-15 | LEPORE PATRICK G | director | 100,000 0.0623% | $1.06 | $105,530 | -19.25% | ||
| 2019-08-20 | Ende Eric J | director | 20,000 0.0126% | $0.66 | $13,200 | +23.73% | ||
| 2019-08-19 | STERN ADAM K | director | 10,400 0.0068% | $0.70 | $7,268 | +20.39% | ||
| 2019-08-19 | Jabbour Jerome D | President and CEO | 14,650 0.0093% | $0.68 | $9,975 | +20.39% | ||
| 2019-08-19 | Ende Eric J | director | 20,000 0.0127% | $0.68 | $13,650 | +20.39% | ||
| 2019-08-16 | LEPORE PATRICK G | director | 100,000 0.0655% | $0.72 | $71,850 | +17.95% | ||
| 2019-06-14 | STERN ADAM K | director | 15,000 0.0105% | $0.80 | $12,000 | +3.27% | ||
| 2019-06-12 | STERN ADAM K | director | 20,000 0.0141% | $0.80 | $15,998 | +4.19% | ||
| 2019-06-12 | Jabbour Jerome D | President and CEO | 12,487 0.0088% | $0.80 | $9,980 | +4.19% | ||
| 2019-06-10 | STERN ADAM K | director | 15,000 0.0103% | $0.82 | $12,300 | -0.91% | ||
| 2019-06-07 | STERN ADAM K | director | 20,000 0.0146% | $0.89 | $17,800 | -2.82% | ||
| 2019-05-31 | STERN ADAM K | director | 80,000 0.0547% | $0.94 | $75,200 | -13.96% | ||
| 2019-05-16 | STERN ADAM K | director | 150,000 0.1064% | $0.95 | $142,500 | -11.51% | ||
| 2019-05-16 | CONRAD HERBERT J | director | 25,000 0.018% | $0.96 | $24,115 | -11.51% |
| Rongen Roelof | Chief Executive Officer | 3539416 55.2499% | $644,173.71 | 1 | 0 | <0.0001% |
| STERN ADAM K | director | 3301983 51.5436% | $600,960.91 | 12 | 0 | <0.0001% |
| MANNINO RAPHAEL J | Chief Scientific Officer | 1424565 22.2373% | $259,270.83 | 1 | 0 | <0.0001% |
| Jabbour Jerome D | President and CEO | 799511 12.4803% | $145,511.00 | 3 | 0 | +16.76% |
| Scibetta James S | director | 418309 6.5298% | $76,132.24 | 1 | 0 | <0.0001% |
| LEPORE PATRICK G | director | 400000 6.244% | $72,800.00 | 4 | 0 | +2% |
| FERRARI STEFANO | director | 203984 3.1842% | $37,125.09 | 1 | 0 | <0.0001% |
| CONRAD HERBERT J | director | 172959 2.6999% | $31,478.54 | 3 | 0 | <0.0001% |
| Ende Eric J | director | 109292 1.706% | $19,891.14 | 2 | 0 | +22.06% |
| Kucinski Keith A | Chief Financial Officer | 94500 1.4751% | $17,199.00 | 2 | 0 | <0.0001% |
$1,848,072 | 66 | -14.67% | $3.77M | |
Matinas BioPharma Holdings, Inc. (MTNB) | $1,138,733 | 28 | -4.94% | $1.17M |
$63,749,694 | 24 | -12.24% | $3.98M | |
$361,849 | 18 | -27.78% | $774,646.00 | |
$8,249,886 | 17 | -47.87% | $1.02M | |
$117,515 | 16 | -27.38% | $3.56M | |
$739,863 | 13 | 5.72% | $3.79M | |
$24,098 | 12 | -21.64% | $2.71M | |
$140,433 | 11 | -66.00% | $741,461.00 | |
$70,828 | 6 | -57.96% | $2.5M | |
$40,324 | 6 | 31.82% | $5.5M | |
$147,504 | 5 | -36.70% | $4.35M | |
$1,184,658 | 4 | -22.17% | $5.08M | |
$1,057,000 | 3 | 5.27% | $4.11M | |
$6,995,384 | 3 | -62.50% | $1.35M | |
$3,309,940 | 2 | -5.66% | $3.85M | |
$4,423 | 2 | 3.27% | $2.86M | |
$16,800 | 1 | -55.91% | $3.79M | |
$37,000 | 1 | 79.42% | $2.3M |
| Increased Positions | 12 | +37.5% | 184,146 | +55.78% |
| Decreased Positions | 8 | -25% | 71,763 | -21.74% |
| New Positions | 8 | New | 181,612 | New |
| Sold Out Positions | 6 | Sold Out | 47,703 | Sold Out |
| Total Postitions | 36 | +12.5% | 442,491 | +34.04% |
| Vanguard Group Inc | $37.00 | 1% | 59,725 | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $35.00 | 0.93% | 55,970 | +476 | +0.86% | 2025-09-30 |
| Blackrock, Inc. | $31.00 | 0.83% | 49,650 | 0 | 0% | 2025-09-30 |
| Sargent Investment Group, Llc | $23.00 | 0.61% | 36,620 | +1,000 | +2.81% | 2025-09-30 |
| Holos Integrated Wealth Llc | $20.00 | 0.54% | 32,480 | 0 | 0% | 2025-06-30 |
| Renaissance Technologies Llc | $18.00 | 0.47% | 28,270 | +3,600 | +14.59% | 2025-09-30 |
| Northern Trust Corp | $14.00 | 0.38% | 22,594 | +22,594 | New | 2025-09-30 |
| State Street Corp | $10.00 | 0.26% | 15,322 | 0 | 0% | 2025-09-30 |
| Two Sigma Securities, Llc | $8.00 | 0.21% | 12,560 | +12,560 | New | 2025-09-30 |
| Hrt Financial Lp | $7.00 | 0.18% | 10,784 | +10,784 | New | 2025-09-30 |